Clinical trial
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the…
NCT00092482 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00092482 |
|---|---|
| Title | Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) |
| Official title | Immunogenicity and Safety of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Consistency Lots for 16- to 23-Year-Old Women With and Additional Immunogenicity Bridge to the Monovalent HPV 16 Vaccine Pilot Manufacturing Lot Study-The F.U.T.U.R.E. Study… |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cervical Cancer, Genital Warts |
| Intervention type | Biological |
| Interventions | V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years |
| Enrollment | 3,882 |
| Start date | Jun 28, 2002 |
| Primary completion | Jun 30, 2004 |
| Completion | Aug 15, 2008 |
| First posted | Sep 27, 2004 |
| Last update posted | Mar 22, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: